Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
Prolixin Enanthate is a long-acting injectable antipsychotic containing fluphenazine enanthate, a first-generation typical antipsychotic used to treat schizophrenia and other psychotic disorders. It is administered via intramuscular injection at extended intervals, providing sustained dopamine antagonism for symptom control and relapse prevention.
As an aging first-generation antipsychotic approaching loss of exclusivity, this product supports a smaller, defensive team focused on legacy patient management rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Prolixin Enanthate offers limited career growth potential due to its maturity and approaching LOE; roles are primarily focused on defending market share in a declining segment rather than launching or scaling new therapies. This assignment is suitable for professionals seeking stability in a legacy product or those developing expertise in managed care and payer negotiations for cost-sensitive markets.
Worked on PROLIXIN ENANTHATE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo